Business Context and Reporting Period
Company: Inmune Bio, Inc. (INMB)
Filing Type: Form 8-K (Current Report)
Date of Report: September 24, 2019
Reporting Period: Single event date (September 24, 2019)
Context: The filing serves as a Regulation FD disclosure to announce a media interview featuring the Company's Co-Founder and CEO, RJ Tesi, M.D., with financial reporter Jason Lin regarding the Company's accomplishments.
Financial Metrics
This Form 8-K is a disclosure of a specific event and does not contain financial statements. The filing text does not provide values for revenue, profit, cash flow, margins, debt, or liquidity.
Material Changes
No material financial changes or operational updates were reported in this filing. The document solely references the publication of a press release concerning a media interview.
Guidance, Outlook, and Risks
Management Commentary: The filing notes that the CEO will discuss the Company's accomplishments in an interview, but the specific content of those accomplishments is not detailed in the 8-K text itself.
Risks and Contingencies: No new risks or contingencies were disclosed in this report.
Unusual Items: None reported.
Key Facts for Investor Verification
- Verify the content of the press release (Exhibit 99.1) to understand the specific "accomplishments" discussed by the CEO.
- Note that the press release is furnished as an exhibit and is not deemed "filed" for purposes of Section 18 of the Exchange Act.
- Confirm the Company's status as an emerging growth company (indicated as yes in the filing).
- Review subsequent filings (e.g., 10-Q or 10-K) for actual financial performance data, as this 8-K contains no financial metrics.